56 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Reinhardt A, Pfister K, Schrimpf D, Stichel D, Sahm F, Reuss DE, Capper D, Wefers AK, Ebrahimi A, Sill M, Felsberg J, Reifenberger G, Becker A, Prinz M, Staszewski O, ... Hartmann C, et al. Anaplastic ganglioglioma - a diagnosis comprising several distinct tumour types. Neuropathology and Applied Neurobiology. e12847. PMID 35977725 DOI: 10.1111/nan.12847  0.43
2021 Suwala AK, Felix M, Friedel D, Stichel D, Schrimpf D, Hinz F, Hewer E, Schweizer L, Dohmen H, Pohl U, Staszewski O, Korshunov A, Stein M, Wongsurawat T, Cheunsuacchon P, ... ... Hartmann C, et al. Oligosarcomas, IDH-mutant are distinct and aggressive. Acta Neuropathologica. PMID 34967922 DOI: 10.1007/s00401-021-02395-z  0.549
2021 Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, Blattner M, Worst B, Heilig CE, Beck K, Horak P, Kreutzfeldt S, Paff E, Stark S, Johann P, ... ... Hartmann C, et al. Sarcoma classification by DNA methylation profiling. Nature Communications. 12: 498. PMID 33479225 DOI: 10.1038/s41467-020-20603-4  0.401
2019 Reinhardt A, Stichel D, Schrimpf D, Koelsche C, Wefers AK, Ebrahimi A, Sievers P, Huang K, Casalini MB, Fernández-Klett F, Suwala A, Weller M, Gramatzki D, Felsberg J, Reifenberger G, ... ... Hartmann C, et al. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications. 7: 163. PMID 31661039 DOI: 10.1186/S40478-019-0801-8  0.613
2019 Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, Schutz PW, Scheie D, Kruse A, Harter PN, Kastelan M, Wagner M, Hartmann C, Benzel J, Maass KK, Khasraw M, et al. MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica. PMID 31414211 DOI: 10.1007/S00401-019-02056-2  0.437
2018 Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE, Koelsche C, Huang K, Wefers AK, Hovestadt V, Sill M, Gramatzki D, Felsberg J, Reifenberger G, Koch A, ... ... Hartmann C, et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica. PMID 29564591 DOI: 10.1007/S00401-018-1837-8  0.688
2018 Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, ... ... Hartmann C, et al. DNA methylation-based classification of central nervous system tumours. Nature. PMID 29539639 DOI: 10.1038/Nature26000  0.635
2016 Schliesser MG, Claus R, Hielscher T, Grimm C, Weichenhan D, Blaes J, Wiestler B, Hau P, Schramm J, Sahm F, Weiß EK, Weiler M, Baer C, Schmidt-Graf F, Schackert G, ... ... Hartmann C, et al. Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget. PMID 27880937 DOI: 10.18632/Oncotarget.13452  0.409
2016 Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Happold C, Galldiks N, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology. PMID 27370396 DOI: 10.1093/Neuonc/Now133  0.371
2016 Kratz A, Sahm F, Schrimpf D, Jones DT, Reuß D, Kölsche C, Huang K, Wefers AK, Hovestadt V, Gramatzki D, Felsberg J, Koch A, Thomale UW, Reifenberger G, Becker A, ... ... Hartmann C, et al. HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA Neuro-Oncology. 18: iii63.2-iii63. DOI: 10.1093/Neuonc/Now073.64  0.606
2015 Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F, Koelsche C, Korshunov A, Olar A, Hartmann C, Reijneveld JC, Wesseling P, Unterberg A, Platten M, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica. 129: 867-73. PMID 25962792 DOI: 10.1007/S00401-015-1438-8  0.419
2014 Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, et al. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6304-13. PMID 25338498 DOI: 10.1158/1078-0432.CCR-14-0951-T  0.356
2014 Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W, Mueller W, Hartmann C, Paulus W, von Deimling A. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathologica. 128: 551-9. PMID 25143301 DOI: 10.1007/S00401-014-1326-7  0.499
2014 Wiestler B, Capper D, Hovestadt V, Sill M, Jones DT, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, et al. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology. 16: 1630-8. PMID 25028501 DOI: 10.1093/Neuonc/Nou138  0.435
2014 Wiestler B, Capper D, Sill M, Jones DT, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A, Weiß EK, Schliesser MG, Radbruch A, Herold-Mende C, Roth P, ... ... Hartmann C, et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica. 128: 561-71. PMID 25008768 DOI: 10.1007/S00401-014-1315-X  0.504
2014 Blaes J, Weiler M, Sahm F, Hentschel B, Osswald M, Czabanka M, Thomé CM, Schliesser MG, Pusch S, Luger S, Winkler F, Radbruch A, Jugold M, Simon M, Steinbach JP, ... ... Hartmann C, et al. NDRG1 prognosticates the natural course of disease in WHO grade II glioma. Journal of Neuro-Oncology. 117: 25-32. PMID 24395351 DOI: 10.1007/s11060-013-1357-2  0.477
2013 Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Böhmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica. 126: 907-15. PMID 24154961 DOI: 10.1007/S00401-013-1195-5  0.486
2013 Wick W, Steinbach JP, Platten M, Hartmann C, Wenz F, von Deimling A, Shei P, Moreau-Donnet V, Stoffregen C, Combs SE. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neuro-Oncology. 15: 1405-12. PMID 23911595 DOI: 10.1093/Neuonc/Not100  0.404
2013 Sahm F, Lass U, Herold-Mende C, von Deimling A, Hartmann C, Mueller W. Analysis of CIC-associated CpG island methylation in oligoastrocytoma. Neuropathology and Applied Neurobiology. 39: 831-6. PMID 23521081 DOI: 10.1111/Nan.12045  0.479
2013 Lass U, Hartmann C, Capper D, Herold-Mende C, von Deimling A, Meiboom M, Mueller W. Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. Brain Pathology (Zurich, Switzerland). 23: 311-8. PMID 23107103 DOI: 10.1111/bpa.12003  0.462
2013 Adachi K, Sasaki H, Nagahisa S, Yoshida K, Hattori N, Nishiyama Y, Kawase T, Hasegawa M, Abe M, Hirose Y, Alentorn A, Marie Y, Poggioli S, Alshehhi H, Boisselier B, ... ... Hartmann C, ... ... Hartmann C, et al. OMICS AND PROGNSTIC MARKERS Neuro-Oncology. 15: iii136-iii155. DOI: 10.1093/Neuonc/Not183  0.573
2012 Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. Plos One. 7: e47663. PMID 23077658 DOI: 10.1371/journal.pone.0047663  0.441
2012 Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathologica. 123: 853-60. PMID 22588899 DOI: 10.1007/S00401-012-0993-5  0.466
2011 Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathologica. 121: 397-405. PMID 21274720 DOI: 10.1007/S00401-011-0802-6  0.495
2010 Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, Hartmann C, von Deimling A. PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathology (Zurich, Switzerland). 20: 298-300. PMID 19744125 DOI: 10.1111/J.1750-3639.2009.00327.X  0.421
2009 Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica. 118: 469-74. PMID 19554337 DOI: 10.1007/S00401-009-0561-9  0.45
2009 Capper D, Gaiser T, Hartmann C, Habel A, Mueller W, Herold-Mende C, von Deimling A, Siegelin MD. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathologica. 117: 445-56. PMID 19214542 DOI: 10.1007/s00401-009-0494-3  0.395
2008 Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica. 116: 597-602. PMID 18985363 DOI: 10.1007/S00401-008-0455-2  0.48
2007 Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6933-7. PMID 18056167 DOI: 10.1158/1078-0432.Ccr-07-0573  0.373
2007 Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G. Long-term survival with glioblastoma multiforme. Brain : a Journal of Neurology. 130: 2596-606. PMID 17785346 DOI: 10.1093/Brain/Awm204  0.306
2007 Holtkamp N, Ziegenhagen N, Malzer E, Hartmann C, Giese A, von Deimling A. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro-Oncology. 9: 291-7. PMID 17504929 DOI: 10.1215/15228517-2007-009  0.329
2007 Simon M, Boström JP, Hartmann C. Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery. 60: 787-98; discussion 7. PMID 17460514 DOI: 10.1227/01.Neu.0000255421.78431.Ae  0.373
2007 Stockhammer F, Thomale UW, Plotkin M, Hartmann C, Von Deimling A. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. Journal of Neurosurgery. 106: 633-7. PMID 17432715 DOI: 10.3171/Jns.2007.106.4.633  0.356
2007 Tews B, Roerig P, Hartmann C, Hahn M, Felsberg J, Blaschke B, Sabel M, Kunitz A, Toedt G, Neben K, Benner A, von Deimling A, Reifenberger G, Lichter P. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Oncogene. 26: 5010-6. PMID 17311001 DOI: 10.1038/Sj.Onc.1210297  0.348
2006 Hartmann C, Sieberns J, Gehlhaar C, Simon M, Paulus W, von Deimling A. NF2 mutations in secretory and other rare variants of meningiomas. Brain Pathology (Zurich, Switzerland). 16: 15-9. PMID 16612978 DOI: 10.1111/J.1750-3639.2006.Tb00557.X  0.348
2006 Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G, Neben K, Hummerich L, von Deimling A, Reifenberger G, Lichter P. Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. International Journal of Cancer. Journal International Du Cancer. 119: 792-800. PMID 16550607 DOI: 10.1002/Ijc.21901  0.378
2006 Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, Estevez-Schwarz L, Mawrin C, Friedrich RE, Mautner VF, von Deimling A. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis. 27: 664-71. PMID 16357008 DOI: 10.1093/Carcin/Bgi273  0.32
2005 Wemmert S, Ketter R, Rahnenführer J, Beerenwinkel N, Strowitzki M, Feiden W, Hartmann C, Lengauer T, Stockhammer F, Zang KD, Meese E, Steudel WI, von Deimling A, Urbschat S. Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia (New York, N.Y.). 7: 883-93. PMID 16242071 DOI: 10.1593/Neo.05307  0.368
2005 Hartmann C, von Deimling A. Oligodendrogliomas: impact of molecular genetics on treatment. Neurology India. 53: 140-8. PMID 16010049 DOI: 10.4103/0028-3886.16394  0.41
2005 Díaz de StÃ¥hl T, Hartmann C, de Bustos C, Piotrowski A, Benetkiewicz M, Mantripragada KK, Tykwinski T, von Deimling A, Dumanski JP. Chromosome 22 tiling-path array-CGH analysis identifies germ-line- and tumor-specific aberrations in patients with glioblastoma multiforme. Genes, Chromosomes & Cancer. 44: 161-9. PMID 15945096 DOI: 10.1002/Gcc.20226  0.398
2005 Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A. PIK3CA mutations in glioblastoma multiforme. Acta Neuropathologica. 109: 639-42. PMID 15924253 DOI: 10.1007/S00401-005-1000-1  0.335
2005 Hartmann C, Mueller W, Lass U, Kamel-Reid S, von Deimling A. Molecular genetic analysis of oligodendroglial tumors. Journal of Neuropathology and Experimental Neurology. 64: 10-4. PMID 15715080 DOI: 10.1093/Jnen/64.1.10  0.548
2005 Rahnenführer J, Beerenwinkel N, Schulz WA, Hartmann C, von Deimling A, Wullich B, Lengauer T. Estimating cancer survival and clinical outcome based on genetic tumor progression scores. Bioinformatics (Oxford, England). 21: 2438-46. PMID 15705654 DOI: 10.1093/Bioinformatics/Bti312  0.331
2004 Holtkamp N, Reuss DE, Atallah I, Kuban RJ, Hartmann C, Mautner VF, Frahm S, Friedrich RE, Algermissen B, Pham VA, Prietz S, Rosenbaum T, Estevez-Schwarz L, von Deimling A. Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathology (Zurich, Switzerland). 14: 258-64. PMID 15446580 DOI: 10.1111/J.1750-3639.2004.Tb00062.X  0.37
2004 Hartmann C, Mueller W, von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. Journal of Molecular Medicine (Berlin, Germany). 82: 638-55. PMID 15322700 DOI: 10.1007/S00109-004-0565-9  0.565
2004 Tallen G, Kaiser I, Krabbe S, Lass U, Hartmann C, Henze G, Riabowol K, von Deimling A. No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. International Journal of Cancer. Journal International Du Cancer. 109: 476-9. PMID 14961591 DOI: 10.1002/Ijc.11715  0.316
2004 Hartmann C, Nümann A, Mueller W, Holtkamp N, Simon M, von Deimling A. Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. International Journal of Cancer. Journal International Du Cancer. 108: 839-44. PMID 14712485 DOI: 10.1002/Ijc.11638  0.562
2004 Kakkassery V, Kruse P, Ruokonen P, Hartmann C, Pleyer U. Erstmanifestation einer Uveitis unter Behandlung mit dem Anti-Tumor-Nekrose-Faktor Etanercept Klinische Monatsblatter Fur Augenheilkunde. 221. DOI: 10.1055/S-2004-837149  0.317
2003 Holtkamp N, Mautner VF, Friedrich RE, Harder A, Hartmann C, Theallier-Janko A, Hoffmann KT, von Deimling A. Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathologica. 107: 159-68. PMID 14673600 DOI: 10.1007/S00401-003-0797-8  0.34
2003 Hartmann C, Mueller W, Lass U, Stockhammer F, von Eckardstein K, Veelken J, Jeuken J, Wick W, von Deimling A. No preferential loss of paternal 19q alleles in oligodendroglial tumors. Annals of Neurology. 54: 256-8. PMID 12891681 DOI: 10.1002/Ana.10649  0.523
2003 Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Research. 63: 1602-7. PMID 12670911  0.716
2003 Heinrich B, Hartmann C, Stemmer-Rachamimov AO, Louis DN, MacCollin M. Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms. International Journal of Cancer. Journal International Du Cancer. 103: 483-8. PMID 12478663 DOI: 10.1002/Ijc.10840  0.671
2002 Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, Jenkins RB, Louis DN. Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Research. 62: 4100-8. PMID 12124348  0.462
2002 Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. The American Journal of Pathology. 161: 313-9. PMID 12107116 DOI: 10.1016/S0002-9440(10)64183-1  0.649
2002 Hartmann C, Johnk L, Sasaki H, Jenkins RB, Louis DN. Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas. Brain Pathology (Zurich, Switzerland). 12: 178-82. PMID 11958371 DOI: 10.1111/J.1750-3639.2002.Tb00432.X  0.668
2000 Park CC, Hartmann C, Folkerth R, Loeffler JS, Wen PY, Fine HA, Black PM, Shafman T, Louis DN. Systemic metastasis in glioblastoma may represent the emergence of neoplastic subclones. Journal of Neuropathology and Experimental Neurology. 59: 1044-50. PMID 11138924 DOI: 10.1093/Jnen/59.12.1044  0.571
Show low-probability matches.